Pathogenesis, Diagnosis, and Treatment of Respiratory Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 482

Special Issue Editor


E-Mail Website
Guest Editor
1. School of Medicine, China Medical University, Taichung, Taiwan
2. Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
Interests: COPD; asthma; interstitial lung disease; lung cancer; pneumonia; tuberculosis; respiratory failure; ARDS; COVID-19; obstructive sleep apnea
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

COVID-19 has had a huge impact on our lives. Thus, we must pay more attention to respiratory diseases, particularly their molecular mechanisms, diagnosis, and treatment. These actions will directly affect and contribute to the survival of human beings.

This Special Issue aims to collect various research articles on respiratory diseases. Studies focusing on the molecular mechanisms, pathogenesis, diagnosis, treatment, and prognosis of these diseases will be prioritized. This Special Issue will improve our understanding of the occurrence of respiratory diseases and possible approaches to early diagnosis and precise treatment.

In this Special Issue, original clinical and basic research articles and reviews are welcome. Research areas may include (but are not limited to) the following: COPD, asthma, interstitial lung disease, lung cancer, pneumonia, tuberculosis, respiratory failure, ARDS, COVID-19, and obstructive sleep apnea. I look forward to receiving your contributions.

Dr. Te-Chun Shen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COPD
  • asthma
  • interstitial lung disease
  • lung cancer
  • pneumonia
  • tuberculosis
  • respiratory failure
  • ARDS
  • COVID-19
  • obstructive sleep apnea

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 5770 KiB  
Article
PGC1-Alpha/Sirt3 Signaling Pathway Mediates the Anti-Pulmonary Fibrosis Effect of Hirudin by Inhibiting Fibroblast Senescence
by Bin He, Qian Zeng, Yumei Tian, Yuyang Luo, Minlin Liao, Wenjie Huang, Bin Wu, Ziqiang Luo, Xiaoting Huang, Wei Liu and Siyuan Tang
Biomedicines 2024, 12(7), 1436; https://doi.org/10.3390/biomedicines12071436 - 27 Jun 2024
Viewed by 336
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease for which there is a lack of effective pharmacological treatments. Hirudin, a natural peptide extracted from leeches, has been used for broad pharmacological purposes. In this study, we investigated the therapeutic effects [...] Read more.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease for which there is a lack of effective pharmacological treatments. Hirudin, a natural peptide extracted from leeches, has been used for broad pharmacological purposes. In this study, we investigated the therapeutic effects of hirudin on IPF and its related mechanism of action. By constructing a mouse model of pulmonary fibrosis and treating it with hirudin in vivo, we found that hirudin exerted anti-fibrotic, anti-oxidative, and anti-fibroblast senescence effects. Moreover, using an in vitro model of stress-induced premature senescence in primary mouse lung fibroblasts and treating with hirudin, we observed inhibition of fibroblast senescence and upregulation of PGC1-alpha and Sirt3 expression. However, specific silencing of PGC1-alpha or Sirt3 suppressed the anti-fibroblast senescence effect of hirudin. Thus, the PGC1-alpha/Sirt3 pathway mediates the anti-fibroblast senescence effect of hirudin, potentially serving as a molecular mechanism underlying its anti-fibrosis and anti-oxidative stress effects exerted on the lungs. Full article
(This article belongs to the Special Issue Pathogenesis, Diagnosis, and Treatment of Respiratory Diseases)
Show Figures

Figure 1

Back to TopTop